|
Market Cap | 1.26B | EPS (ttm) | -0.99 |
P/E | - | EPS this Y | 33.15% |
Forward P/E | - | EPS next Y | 24.88% |
PEG | - | EPS past 5Y | -80.78% |
P/S | 2518.74 | EPS next 5Y | - |
P/B | 7.57 | EPS Q/Q | 28.45% |
Dividend | - | Sales Q/Q | - |
Insider Own | 16.19% | Inst Own | 37.01% |
Insider Trans | 0.00% | Inst Trans | -1.28% |
Short Float | 27.04% | Earnings | May 15/a |
Analyst Recom | 1.00 | Target Price | 12.85 |
Avg Volume | 5.84M | 52W Range | 1.97 - 7.10 |
|
|
|
AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX. |
|
|
|
Market Cap | 9.68B | EPS (ttm) | 8.04 |
P/E | 23.57 | EPS this Y | 34.13% |
Forward P/E | 21.59 | EPS next Y | 4.15% |
PEG | 1.31 | EPS past 5Y | 41.99% |
P/S | 2.17 | EPS next 5Y | 18.00% |
P/B | 9.24 | EPS Q/Q | 564.60% |
Dividend | - | Sales Q/Q | 22.10% |
Insider Own | 1.94% | Inst Own | 101.44% |
Insider Trans | -42.69% | Inst Trans | -5.38% |
Short Float | 9.91% | Earnings | May 29/b |
Analyst Recom | 2.50 | Target Price | 156.01 |
Avg Volume | 1.62M | 52W Range | 29.70 - 154.87 |
|
|
|
Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, EMEA and APAC. The Americas segment includes operations in North America and South America. The EMEA segment includes operations in Europe, the Middle East and Africa. The APAC segment includes operations in the Asia-Pacific region, including Asia and Oceania. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Horowitz Fran | Chief Executive Officer | Apr 18 '24 | Sale | 110.61 | 400,000 | 44,244,000 | 525,520 | Apr 22 06:26 PM | Scott Kristin A. | President-Global Brands | Mar 25 '24 | Option Exercise | 0.00 | 15,734 | 0 | 62,540 | Mar 26 05:43 PM | Rust Jay | EVP Human Resources | Mar 25 '24 | Option Exercise | 0.00 | 3,680 | 0 | 5,759 | Mar 26 05:43 PM | Lipesky Scott D. | EVP, COO and CFO | Mar 25 '24 | Option Exercise | 0.00 | 7,867 | 0 | 101,513 | Mar 26 05:43 PM | HENCHEL GREGORY J | SVP, Gen Cnsl & Secy | Mar 25 '24 | Option Exercise | 0.00 | 3,147 | 0 | 31,347 | Mar 26 05:43 PM |
|
|
|
|
Market Cap | 1.05B | EPS (ttm) | 0.05 |
P/E | 686.28 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 7.60 | EPS Q/Q | -133.94% |
Dividend | - | Sales Q/Q | - |
Insider Own | 91.27% | Inst Own | 0.84% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.27% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 27.63K | 52W Range | 5.59 - 31.63 |
|
|
|
Logistic Properties of the Americas develops, builds and operates logistic real estate properties. The company was headquartered in San Rafael de Escazu, Costa Rica. |
|
| |
|
Market Cap | 197.42M | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 25.31 | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | 45.38% | Inst Own | - |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.07% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 1.15M | 52W Range | 3.25 - 6.27 |
|
|
|
NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY. |
|
|
|
Market Cap | 165.78M | EPS (ttm) | -1.14 |
P/E | - | EPS this Y | -16.55% |
Forward P/E | - | EPS next Y | 32.40% |
PEG | - | EPS past 5Y | 48.08% |
P/S | - | EPS next 5Y | - |
P/B | 2.34 | EPS Q/Q | -10.10% |
Dividend | - | Sales Q/Q | - |
Insider Own | 22.84% | Inst Own | 60.94% |
Insider Trans | 84.73% | Inst Trans | -0.33% |
Short Float | 1.00% | Earnings | May 15/a |
Analyst Recom | 1.00 | Target Price | 10.00 |
Avg Volume | 540.33K | 52W Range | 0.72 - 3.72 |
|
|
May-22-24 07:23AM
|
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
(InvestorPlace) -6.33% |
06:27AM
|
Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk
(FierceBiotech.com) |
May-21-24 04:05PM
|
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
(GlobeNewswire) +6.76% |
May-15-24 10:54PM
|
RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024
(InvestorPlace) |
04:05PM
|
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
(GlobeNewswire) |
Apr-23-24 08:00AM
|
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
(GlobeNewswire) -19.21% |
Mar-20-24 02:33PM
|
Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More
(Insider Monkey) |
Mar-06-24 07:30AM
|
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
(GlobeNewswire) |
Feb-13-24 04:05PM
|
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
(GlobeNewswire) |
Jan-24-24 08:00AM
|
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
(GlobeNewswire) +6.37% |
|
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Evans Daron | CFO | May 24 '24 | Buy | 3.23 | 2,942 | 9,503 | 13,000 | May 28 02:48 PM | ROBERTS BRIAN KENNETH | Chief Medical Officer | May 23 '24 | Buy | 2.69 | 7,500 | 20,138 | 50,052 | May 28 02:56 PM | Evans Daron | CFO | May 23 '24 | Buy | 2.85 | 58 | 165 | 10,058 | May 28 02:48 PM | ROBERTS BRIAN KENNETH | Chief Medical Officer | Mar 28 '24 | Buy | 2.55 | 500 | 1,275 | 1,076 | Mar 29 11:08 AM | Evans Daron | CFO | Mar 15 '24 | Buy | 1.69 | 20,000 | 33,830 | 20,000 | Mar 19 09:17 AM |
|
|
| |
|
Market Cap | 257.99M | EPS (ttm) | -0.63 |
P/E | - | EPS this Y | 152.86% |
Forward P/E | 12.12 | EPS next Y | 29.12% |
PEG | - | EPS past 5Y | 26.89% |
P/S | 8.35 | EPS next 5Y | - |
P/B | 3.46 | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | 2.90% | Inst Own | 0.15% |
Insider Trans | 0.00% | Inst Trans | 8.95% |
Short Float | 0.18% | Earnings | May 14/a |
Analyst Recom | 1.29 | Target Price | 10.20 |
Avg Volume | 7.69K | 52W Range | 2.89 - 4.75 |
|
|
|
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-Francois Mouney, Florence Sejourne, and Bart Staels in September 1999 and is headquartered in Loos, France. |
|
|
|
Market Cap | 73.65M | EPS (ttm) | 0.02 |
P/E | 769.08 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 5.62 | EPS Q/Q | -269.23% |
Dividend | - | Sales Q/Q | - |
Insider Own | 58.75% | Inst Own | 19.31% |
Insider Trans | 0.00% | Inst Trans | 100.81% |
Short Float | 0.04% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 8.41K | 52W Range | 10.28 - 11.76 |
|
|
|
Clean Energy Special Situations Corp. is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination. The company was founded on October 2, 2020 and is headquartered in New York, NY. |
|
| |
|
Market Cap | 7.96B | EPS (ttm) | -5.24 |
P/E | - | EPS this Y | 15.87% |
Forward P/E | - | EPS next Y | 14.44% |
PEG | - | EPS past 5Y | -4.82% |
P/S | 25.22 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 9.69% |
Dividend | - | Sales Q/Q | 15.77% |
Insider Own | 3.00% | Inst Own | 100.61% |
Insider Trans | -5.68% | Inst Trans | -4.49% |
Short Float | 6.89% | Earnings | May 09/b |
Analyst Recom | 1.06 | Target Price | 58.44 |
Avg Volume | 2.28M | 52W Range | 18.31 - 50.10 |
|
|
|
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Adsett Roger | Chief Operating Officer | May 17 '24 | Sale | 25.09 | 5,945 | 149,160 | 149,275 | May 17 04:15 PM | Flammer Martina M.D. | Chief Medical Officer | May 17 '24 | Sale | 25.09 | 4,642 | 116,468 | 106,134 | May 17 04:16 PM | Lewis William | Chair and CEO | May 14 '24 | Sale | 25.52 | 22,198 | 566,493 | 384,125 | May 15 04:34 PM | Bonstein Sara | Chief Financial Officer | May 14 '24 | Sale | 25.32 | 11,088 | 280,748 | 117,481 | May 15 04:32 PM | Flammer Martina M.D. | Chief Medical Officer | May 14 '24 | Sale | 25.47 | 10,640 | 271,001 | 110,776 | May 15 04:33 PM |
|
|
|
|
Market Cap | 600.35M | EPS (ttm) | 0.96 |
P/E | 44.01 | EPS this Y | -479.69% |
Forward P/E | - | EPS next Y | 97.94% |
PEG | 4.40 | EPS past 5Y | 20.22% |
P/S | 4.20 | EPS next 5Y | 10.00% |
P/B | 4.84 | EPS Q/Q | 103.16% |
Dividend | - | Sales Q/Q | 17.50% |
Insider Own | 4.24% | Inst Own | 89.40% |
Insider Trans | 0.00% | Inst Trans | 0.25% |
Short Float | 3.67% | Earnings | May 01/b |
Analyst Recom | 2.50 | Target Price | 52.33 |
Avg Volume | 74.58K | 52W Range | 17.73 - 39.41 |
|
|
|
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
BEDOYA JOSE H | Director | Feb 08 '24 | Option Exercise | 23.95 | 3,932 | 94,171 | 30,108 | Feb 12 04:18 PM | KNIGHT SUSAN E | Director | Feb 05 '24 | Option Exercise | 23.95 | 3,932 | 94,171 | 36,267 | Feb 07 04:27 PM | DANTZKER DAVID | Director | Jan 19 '24 | Option Exercise | 23.95 | 3,932 | 94,171 | 40,094 | Jan 23 05:46 PM | KALICH RONALD B SR | Director | Dec 27 '23 | Option Exercise | 23.95 | 3,932 | 94,171 | 38,529 | Dec 29 04:26 PM | Stich Joseph J. | SVP HR and IVD | Nov 15 '23 | Option Exercise | 23.95 | 17,121 | 410,048 | 72,433 | Nov 17 04:07 PM |
|
|
|
|
Market Cap | 95.22M | EPS (ttm) | -1.53 |
P/E | - | EPS this Y | -6.02% |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -25.01% |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | -22.21% |
Dividend | - | Sales Q/Q | - |
Insider Own | 21.50% | Inst Own | 3.03% |
Insider Trans | 15.21% | Inst Trans | 101.50% |
Short Float | 7.15% | Earnings | Nov 07/b |
Analyst Recom | 1.00 | Target Price | 14.00 |
Avg Volume | 401.92K | 52W Range | 0.82 - 4.29 |
|
|
|
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Smith Stan | Director | Apr 25 '24 | Buy | 2.03 | 147,492 | 299,409 | 1,005,060 | Apr 26 05:30 PM | Louie Ngar Yee | Director | Apr 25 '24 | Buy | 2.03 | 19,665 | 39,920 | 1,167,189 | Apr 26 05:33 PM | Smith Stan | Director | Mar 14 '24 | Buy | 1.17 | 170,940 | 200,000 | 857,568 | Mar 15 07:11 PM | Louie Ngar Yee | Director | Mar 14 '24 | Buy | 1.17 | 170,940 | 200,000 | 1,147,524 | Mar 15 07:09 PM | Luput Cristian | Director | Mar 14 '24 | Buy | 1.17 | 69,282 | 81,060 | 367,350 | Mar 15 07:08 PM |
|
|
|